Male and Female Fertility: Prevention and Monitoring Hodgkin' Lymphoma and Diffuse Large B-Cell Lymphoma Adult Survivors. A Systematic Review by the Fondazione Italiana Linfomi

被引:16
|
作者
Viviani, Simonetta [1 ]
Caccavari, Valentina [2 ]
Gerardi, Chiara [3 ]
Ramadan, Safaa [1 ,4 ]
Allocati, Eleonora [3 ]
Minoia, Carla [5 ]
Guarini, Attilio [5 ]
Di Russo, Anna [6 ]
机构
[1] European Inst Oncol IRCCS, Div Oncohematol IEO, I-20141 Milan, Italy
[2] Ist Clin Citta Studi, Assisted Reprod Unit, I-20131 Milan, Italy
[3] Ist Ric Farmacol Mario Negri IRCCS, I-20156 Milan, Italy
[4] Cairo Univ, Natl Canc Inst, Dept Med Oncol, Cairo 11796, Egypt
[5] IRCCS Ist Tumori Giovanni Paolo II, Hematol Unit, I-70124 Bari, Italy
[6] Fdn IRCCS Ist Nazl Tumori Milano, Dept Radiat Oncol, I-20133 Milan, Italy
关键词
hodgkin lymphoma; diffuse large B-cell lymphoma; chemotherapy; radiation therapy; fertility preservation; infertility; gonadotoxicity; oocyte cryopreservation; ovarian tissue cryopreservation; pregnancy; PREMATURE OVARIAN FAILURE; HORMONE AGONIST; GONADAL-FUNCTION; PREGNANCY RATE; YOUNG-WOMEN; FOLLOW-UP; CHEMOTHERAPY; CRYOPRESERVATION; PRESERVATION; OUTCOMES;
D O I
10.3390/cancers13122881
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Patients with Hodgkin lymphoma or diffuse large B-cell lymphoma treated with chemotherapy, with or without radiation therapy on pelvic nodes, may suffer permanent damage to their reproductive function, which significantly affects their quality of life. Established gamete cryopreservation techniques, including the freezing of embryos, oocytes, spermatozoa, ovarian and testicular tissue, can, nowadays, be offered to any adult patient candidate receiving gonadotoxic therapy who is interested in preserving future fertility. In order to offer updated information on anticancer treatment harm and to better advise patients on fertility preservation options, Fondazione Italiana Linfomi (FIL) researchers conducted this systematic review to evaluate the frequency of treatment-related infertility, fertility preservation options, fertility assessment measures, and the optimal interval between end of treatment and conception in adult lymphoma patients. Background: Adult patients with Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL) have prolonged survival but face the risk of treatment-induced impaired fertility. This systematic review, conducted by Fondazione Italiana Linfomi (FIL) researchers, aims to evaluate the incidence of treatment-related infertility, fertility preservation options, fertility assessment measures, and the optimal interval between the end of treatment and conception. Methods: MEDLINE, the Cochrane Library, and EMBASE were systematically searched up to September 2020 for published cohort, case-control, and cross-sectional studies on fertility issues. Results: Forty-five eligible studies were identified. Gonadotoxicity was related to sex, type and dosage of treatment, and, in females, to age. After receiving alkylating-agent-containing regimens, less than 30% of males recovered spermatogenesis, and 45% of females >= 30 years in age retained regular menstrual cycles. Sperm cryopreservation was offered to the majority of patients; sperm utilization resulted in a 33-61% pregnancy rate. After ovarian tissue transplantation, the spontaneous pregnancy and live birth rates were 38% and 23%; after IVF, the live birth rate was 38.4%. No data could be extracted on the utilization rate of cryopreserved mature oocytes. The results of studies on GnRH analogs are controversial; therefore, their use should not be considered an alternative to established cryopreservation techniques. Sperm count, FSH, and inhibin-B levels were appropriate measures to investigate male fertility; serum AMH levels and antral follicle count were the most appropriate markers for ovarian reserve. No data could be found regarding the optimal interval between the end of treatment and conception. Conclusions: The risk of infertility should be discussed with adult lymphoma patients at the time of diagnosis, and fertility preservation options should be proposed before first-line treatment with alkylating-agent-containing regimens.
引用
收藏
页数:29
相关论文
共 50 条
  • [31] Systematic Analysis of Competing Endogenous RNA Networks in Diffuse Large B-Cell Lymphoma and Hodgkin's Lymphoma
    Kang, Juanjuan
    Yao, Pengcheng
    Tang, Qiang
    Wang, Ying
    Zhou, Yuwei
    Huang, Jian
    FRONTIERS IN GENETICS, 2020, 11
  • [32] Mycosis Fungoides with Recurrent Hodgkin's Lymphoma and Diffuse Large B-cell Lymphoma
    Miyagaki, Tomomitsu
    Sugaya, Makoto
    Minatani, Yosaku
    Fujita, Hideki
    Hangaishi, Akira
    Kurokawa, Mineo
    Takazawa, Yutaka
    Tamaki, Kunihiko
    ACTA DERMATO-VENEREOLOGICA, 2009, 89 (04) : 421 - 422
  • [33] A composite lymphoma combining a Hodgkin lymphoma and a marginal zone lymphoma transformed into a diffuse large B-cell lymphoma
    Auditeau, Claire
    Lambotte, Olivier
    Feriel, Joffrey
    Lazure, Thierry
    Turhan, Ali
    Aumont, Cedric
    CLINICAL CASE REPORTS, 2018, 6 (12): : 2341 - 2346
  • [34] Simultaneous Presence of Follicular Lymphoma, Diffuse Large B-cell Lymphoma, and Hodgkin-like Lymphoma
    Papoudou-Bai, Alexandra
    Marinos, Leonidas
    Papathanasiou, Konstantina
    Kanavaros, Panagiotis
    Kapsali, Eleni
    TURKISH JOURNAL OF HEMATOLOGY, 2018, 35 (04) : 308 - 309
  • [35] Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi
    Chiappella, Annalisa
    Tucci, Alessandra
    Castellino, Alessia
    Pavone, Vincenzo
    Baldi, Ileana
    Carella, Angelo Michele
    Orsucci, Lorella
    Zanni, Manuela
    Salvi, Flavia
    Liberati, Anna Marina
    Gaidano, Gianluca
    Bottelli, Chiara
    Rossini, Bernardo
    Perticone, Sonia
    De Masi, Pasqualina
    Ladetto, Marco
    Ciccone, Giovannino
    Palumbo, Antonio
    Rossi, Giuseppe
    Vitolo, Umberto
    HAEMATOLOGICA, 2013, 98 (11) : 1732 - 1738
  • [36] Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi
    Zaja, Francesco
    Salvi, Flavia
    Rossi, Maura
    Sabattini, Elena
    Evangelista, Andrea
    Ciccone, Giovannino
    Angelucci, Emanuele
    Gaidano, Gianluca
    Zanni, Manuela
    Ladetto, Marco
    Chiappella, Annalisa
    Vitolo, Umberto
    Zinzani, Pier Luigi
    Califano, Catello
    Tucci, Alessandra
    Patti, Caterina
    Pileri, Stefano A.
    Lenti, Valentina
    Piccaluga, Pier Paolo
    Cavallo, Federica
    Volpetti, Stefano
    Perali, Giulia
    Assouline, Sarit
    Mann, Koren Kathleen
    Morin, Ryan
    Alcaide, Miguel
    Bushell, Kevin
    Fanin, Renato
    Levis, Alessandro
    LEUKEMIA & LYMPHOMA, 2018, 59 (12) : 2904 - 2910
  • [37] Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review
    Decruyenaere, Philippe
    Offner, Fritz
    Vandesompele, Jo
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2021, 10 (01)
  • [38] MicroRNAs as novel biomarkers in diffuse large B-cell lymphoma - a systematic review
    Jorgensen, Laura Krogh
    Poulsen, Mette Ostergaard
    Laursen, Maria Bach
    Marques, Sara Correia
    Johnsen, Hans E.
    Bogsted, Martin
    Dybkaer, Karen
    DANISH MEDICAL JOURNAL, 2015, 62 (05):
  • [39] Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review
    Philippe Decruyenaere
    Fritz Offner
    Jo Vandesompele
    Experimental Hematology & Oncology, 10
  • [40] Prevention of CNS relapse in diffuse large B-cell lymphoma
    Kridel, Robert
    Dietrich, Pierre-Yves
    LANCET ONCOLOGY, 2011, 12 (13): : 1258 - 1266